|
1
|
Pan P, Yu J and Wang LS: Colon cancer:
What we eat. Surg Oncol Clin N Am. 27:243–267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Araghi M, Soerjomataram I, Jenkins M,
Brierley J, Morris E, Bray F and Arnold M: Global trends in
colorectal cancer mortality: Projections to the year 2035. Int J
Cancer. 144:2992–3000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Chen Z and Li J: The current
status of treatment for colorectal cancer in China: A systematic
review. Medicine (Baltimore). 96:e82422017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pardini B, Kumar R, Naccarati A, Novotny
J, Prasad RB, Forsti A, Hemminki K, Vodicka P and Bermejo JL:
5-Fluorouracil-based chemotherapy for colorectal cancer and
MTHFR/MTRR genotypes. Br J Clin Pharmacol. 72:162–163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y,
Coudert B, et al: Phase III multicenter randomized trial of
oxaliplatin added to chronomodulated fluorouracil-leucovorin as
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
18:136–147. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khan M, Saif A, Sandler S and Mirrakhimov
AE: Idelalisib for the treatment of chronic lymphocytic leukemia.
ISRN Oncol. 2014:9318582014.PubMed/NCBI
|
|
10
|
Zhao H, Zhang Y, Sun J, Zhan C and Zhao L:
Raltitrexed inhibits HepG2 cell proliferation via G0/G1 cell cycle
arrest. Oncol Res. 23:237–248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pivot X, Wadler S, Kelly C, Ruxer R,
Tortochaux J, Stern J, Belpomme D, Humblet Y, Domenge C, Clendeninn
N, et al: Result of two randomized trials comparing nolatrexed
(Thymitaq™) versus methotrexate in patients with recurrent head and
neck cancer. Ann Oncol. 12:1595–1599. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen KT, Hour MJ, Tsai SC, Chung JG, Kuo
SC, Lu CC, Chiu YJ, Chuang YH and Yang JS: The novel synthesized
6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10)
compound exhibits anti-metastatic effects in human osteosarcoma U-2
OS cells through targeting insulin-like growth factor-I receptor.
Int J Oncol. 39:611–619. 2011.PubMed/NCBI
|
|
13
|
Yang JS, Hour MJ, Huang WW, Lin KL, Kuo SC
and Chung JG: MJ-29 inhibits tubulin polymerization, induces
mitotic arrest, and triggers apoptosis via cyclin-dependent kinase
1-mediated Bcl-2 phosphorylation in human leukemia U937 cells. J
Pharmacol Exp Ther. 334:477–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hour MJ, Tsai SC, Wu HC, Lin MW, Chung JG,
Wu JB, Chiang JH, Tsuzuki M and Yang JS: Antitumor effects of the
novel quinazolinone MJ-33: Inhibition of metastasis through the
MAPK, AKT, NF-κB and AP-1 signaling pathways in DU145 human
prostate cancer cells. Int J Oncol. 41:1513–1519. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Donnell JS, Massi D, Teng MWL and
Mandala M: PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
Semin Cancer Biol. 48:91–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nitulescu GM, Van De Venter M, Nitulescu
G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis
A, Tsoukalas D, et al: The Akt pathway in oncology therapy and
beyond (Review). Int J Oncol. 53:2319–2331. 2018.PubMed/NCBI
|
|
17
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang CH, Lee CY, Lu CC, Tsai FJ, Hsu YM,
Tsao JW, Juan YN, Chiu HY, Yang JS and Wang CC: Resveratrol-induced
autophagy and apoptosis in cisplatin-resistant human oral cancer
CAR cells: A key role of AMPK and Akt/mTOR signaling. Int J Oncol.
50:873–882. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu J, Zhang S, Wang R, Wu X, Zeng L and Fu
Z: Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by
suppressing the PI3K/AKT signaling pathway. Biosci Rep.
37:BSR201604472017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marino G, Niso-Santano M, Baehrecke EH and
Kroemer G: Self-consumption: The interplay of autophagy and
apoptosis. Nat Rev Mol Cell Biol. 15:81–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Denton D and Kumar S: Autophagy-dependent
cell death. Cell Death Differ. 26:605–616. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumar S, Guru SK, Pathania AS, Mupparapu
N, Kumar A, Malik F, Bharate SB, Ahmed QN, Vishwakarma RA and
Bhushan S: A novel quinazolinone derivative induces cytochrome c
interdependent apoptosis and autophagy in human leukemia MOLT-4
cells. Toxicol Rep. 1:1013–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawai K, Viars C, Arden K, Tarin D,
Urquidi V and Goodison S: Comprehensive karyotyping of the HT-29
colon adenocarcinoma cell line. Genes Chromosomes Cancer. 34:1–8.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S, Mazzucchelli L, et al: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Plasencia C, Abad A, Martinez-Balibrea E
and Taron M: Antiproliferative effects of ZD0473 (AMD473) in
combination with 5-Fluorouracil or SN38 in human colorectal cancer
cell lines. Invest New Drugs. 22:399–409. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee HP, Chen PC, Wang SW, Fong YC, Tsai
CH, Tsai FJ, Chung JG, Huang CY, Yang JS, Hsu YM, et al: Plumbagin
suppresses endothelial progenitor cell-related angiogenesis in
vitro and in vivo. J Functional Foods. 52:537–544. 2019. View Article : Google Scholar
|
|
27
|
Huang TY, Peng SF, Huang YP, Tsai CH, Tsai
FJ, Huang CY, Tang CH, Yang JS, Hsu YM, Yin MC, et al:
Combinational treatment of all-trans retinoic acid (ATRA) and
bisdemethoxycurcumin (BDMC)-induced apoptosis in liver cancer Hep3B
cells. J Food Biochem. 44:e131222020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu CC, Yang JS, Chiang JH, Hour MJ, Lin
KL, Lee TH and Chung JG: Cell death caused by quinazolinone HMJ-38
challenge in oral carcinoma CAL 27 cells: Dissections of
endoplasmic reticulum stress, mitochondrial dysfunction and tumor
xenografts. Biochim Biophys Acta. 1840:2310–2320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beberok A, Wrzesniok D, Rok J, Rzepka Z,
Respondek M and Buszman E: Ciprofloxacin triggers the apoptosis of
human triple-negative breast cancer MDA-MB-231 cells via the
p53/Bax/Bcl-2 signaling pathway. Int J Oncol. 52:1727–1737.
2018.PubMed/NCBI
|
|
30
|
Gelles JD and Chipuk JE: Robust
high-throughput kinetic analysis of apoptosis with real-time
high-content live-cell imaging. Cell Death Dis. 7:e24932016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee CF, Chiang NN, Lu YH, Huang YS, Yang
JS, Tsai SC, Lu CC and Chen FA: Benzyl isothiocyanate (BITC)
triggers mitochondria-mediated apoptotic machinery in human
cisplatin-resistant oral cancer CAR cells. Biomedicine (Taipei).
8:152018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin CC, Chen KB, Tsai CH, Tsai FJ, Huang
CY, Tang CH, Yang JS, Hsu YM, Peng SF and Chung JG: Casticin
inhibits human prostate cancer DU 145 cell migration and invasion
via Ras/Akt/NF-κB signaling pathways. J Food Biochem.
43:e129022019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang JH and Xu M: DNA fragmentation in
apoptosis. Cell Res. 10:205–211. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu CC, Chiang JH, Tsai FJ, Hsu YM, Juan
YN, Yang JS and Chiu HY: Metformin triggers the intrinsic apoptotic
response in human AGS gastric adenocarcinoma cells by activating
AMPK and suppressing mTOR/AKT signaling. Int J Oncol. 54:1271–1281.
2019.PubMed/NCBI
|
|
36
|
Dohle W, Jourdan FL, Menchon G, Prota AE,
Foster PA, Mannion P, Hamel E, Thomas MP, Kasprzyk PG, Ferrandis E,
et al: Quinazolinone-based anticancer agents: Synthesis,
antiproliferative SAR, antitubulin activity, and tubulin co-crystal
structure. J Med Chem. 61:1031–1044. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rahman MU, Jeyabalan G, Saraswat P,
Parveen G, Khan S and Yar MS: Quinazolines and anticancer activity:
A current perspectives. Synthetic Communications. 47:379–408. 2017.
View Article : Google Scholar
|
|
38
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He L, Zhu H, Zhou S, Wu T, Wu H, Yang H,
Mao H, SekharKathera C, Janardhan A, Edick AM, et al: Wnt pathway
is involved in 5-FU drug resistance of colorectal cancer cells. Exp
Mol Med. 50:1012018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maiuthed A, Ninsontia C, Erlenbach-Wuensch
K, Ndreshkjana B, Muenzner JK, Caliskan A, Husayn AP, Chaotham C,
Hartmann A, Roehe AV, et al: Cytoplasmic p21 mediates
5-fluorouracil resistance by inhibiting pro-apoptotic Chk2. Cancers
(Basel). 10:3732018. View Article : Google Scholar
|
|
41
|
Ravanan P, Srikumar IF and Talwar P:
Autophagy: The spotlight for cellular stress responses. Life Sci.
188:53–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sever ON and Demir OG: Autophagy: Cell
death or survive mechanism. J Oncol Sci. 3:37–44. 2017. View Article : Google Scholar
|
|
43
|
Xia X, Wang L, Zhang X, Wang S, Lei L,
Cheng L, Xu Y, Sun Y, Hang B, Zhang G, et al: Halofuginone-induced
autophagy suppresses the migration and invasion of MCF-7 cells via
regulation of STMN1 and p53. J Cell Biochem. 119:4009–4020. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mizushima N, Yoshimori T and Ohsumi Y: The
role of Atg proteins in autophagosome formation. Annu Rev Cell Dev
Biol. 27:107–132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu
HL, Yang C and Liu HF: p62 links the autophagy pathway and the
ubiqutin-proteasome system upon ubiquitinated protein degradation.
Cell Mol Biol Lett. 21:292016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang JS, Lu CC, Kuo SC, Hsu YM, Tsai SC,
Chen SY, Chen YT, Lin YJ, Huang YC, Chen CJ, et al: Autophagy and
its link to type II diabetes mellitus. Biomedicine (Taipei).
7:82017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao E and Czaja MJ: Transcription factor
EB: A central regulator of both the autophagosome and lysosome.
Hepatology. 55:1632–1634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hussain A, Qazi AK, Mupparapu N, Guru SK,
Kumar A, Sharma PR, Singh SK, Singh P, Dar MJ, Bharate SB, et al:
Modulation of glycolysis and lipogenesis by novel PI3K selective
molecule represses tumor angiogenesis and decreases colorectal
cancer growth. Cancer Lett. 374:250–260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jackman AL, Kimbell R, Brown M, Brunton L,
Harrap KR, Wardleworth JM and Boyle FT: The antitumour activity of
ZD9331, a non-polyglutamatable quinazoline thymidylate synthase
inhibitor. Adv Exp Med Biol. 370:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Benepal TS and Judson I: ZD9331: Discovery
to clinical development. Anticancer Drugs. 16:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hussain A, Qazi AK, Mupparapu N, Kumar A,
Mintoo MJ, Mahajan G, Sharma PR, Singh SK, Bharate SB, Zargar MA,
et al: A novel PI3K axis selective molecule exhibits potent tumor
inhibition in colorectal carcinogenesis. Mol Carcinog.
55:2135–2155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang W and Cassidy J: Constitutive nuclear
factor-kappa B mRNA, protein overexpression and enhanced
DNA-binding activity in thymidylate synthase inhibitor-resistant
tumour cells. Br J Cancer. 88:624–629. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rajitha B, Belalcazar A, Nagaraju GP,
Shaib WL, Snyder JP, Shoji M, Pattnaik S, Alam A and El-Rayes BF:
Inhibition of NF-κB translocation by curcumin analogs induces G0/G1
arrest and downregulates thymidylate synthase in colorectal cancer.
Cancer Lett. 373:227–233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Qiu T, Xiang X, Lei W, Hao C, Zhang L,
Feng M, Yu F, Li J and Xiong J: Establishment and biological
characterization of 5-fluorouracil-resistant human colon cancer
HT-29/5-FU cell line. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
31:328–332. 2015.(In Chinese). PubMed/NCBI
|
|
55
|
Gozuacik D and Kimchi A: Autophagy as a
cell death and tumor suppressor mechanism. Oncogene. 23:2891–1906.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ito S, Koshikawa N, Mochizuki S and
Takenaga K: 3-Methyladenine suppresses cell migration and invasion
of HT1080 fibrosarcoma cells through inhibiting phosphoinositide
3-kinases independently of autophagy inhibition. Int J Oncol.
31:261–268. 2007.PubMed/NCBI
|
|
57
|
Kawaguchi T, Miyazawa K, Moriya S, Ohtomo
T, Che XF, Naito M, Itoh M and Tomoda A: Combined treatment with
bortezomib plus bafilomycin A1 enhances the cytocidal effect and
induces endoplasmic reticulum stress in U266 myeloma cells:
Crosstalk among proteasome, autophagy-lysosome and ER stress. Int J
Oncol. 38:643–654. 2011.PubMed/NCBI
|
|
58
|
Liu X, Sun K, Wang H and Dai Y: Inhibition
of autophagy by chloroquine enhances the antitumor efficacy of
sorafenib in glioblastoma. Cell Mol Neurobiol. 36:1197–1208. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zheng X, Jin X, Li F, Liu X, Liu Y, Ye F,
Li P, Zhao T and Li Q: Inhibiting autophagy with chloroquine
enhances the anti-tumor effect of high-LET carbon ions via ER
stress-related apoptosis. Med Oncol. 34:252017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Masud Alam M, Kariya R, Kawaguchi A,
Matsuda K, Kudo E and Okada S: Inhibition of autophagy by
chloroquine induces apoptosis in primary effusion lymphoma in vitro
and in vivo through induction of endoplasmic reticulum stress.
Apoptosis. 21:1191–1201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li J, Hou N, Faried A, Tsutsumi S,
Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann
Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu T, Zhang J, Li K, Deng L and Wang H:
Combination of an autophagy inducer and an autophagy inhibitor: A
smarter strategy emerging in cancer therapy. Front Pharmacol.
11:4082020. View Article : Google Scholar : PubMed/NCBI
|
